Business
CSL (ASX:CSL) share price on watch after terminating COVID-19 vaccine trial
The CSL Limited (ASX: CSL) share price will be one to watch on Friday after the release of an update on its COVID-19 vaccine candidate.
What did CSL announce?
This morning CSL and the University of Queensland (UQ) announced results from the Phase 1 trial of the UQ-CSL v451 COVID-19 vaccine.
According to the release, the vaccine has shown that it elicits a robust response towards the virus and has a strong safety profile.
And while there were no serious adverse events or safety concerns reported, following agreement with the Australian Government, CSL will not progress the vaccine candidate to Phase 2/3 clinical trials.
Why is it not going any further?
The release explains that the Phase 1 data showed the generation of antibodies…
-
General16 hours agoVictorian school teacher charged with soliciting child abuse material
-
Business24 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business23 hours agoHere’s what analysts expect for the BHP share price in the coming year
-
General23 hours agoPatients speak out after Brisbane doctor accused of ‘excessive’ pap smears, kissing woman on lips